Drug Trial Radar · NCT07907991
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Mar 10, 2027
Primary completion
Nov 12, 2029
Study completion Dec 10, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 40 years and older who have chronic obstructive pulmonary disease (COPD) with ongoing symptoms. People can join the study if they are at risk of COPD flare-ups (also called acute exacerbations or sudden worsening of COPD symptoms) even though they use their usual inhaled or oral COPD medicines. They must have had at least 2 moderate COPD flare-ups or at least 1 severe COPD flare-up in the past year, including at least 1 while taking their current COPD treatment. People must also have a blood test result showing less than 300 eosinophils (a type of white blood cell) per microliter. The purpose of this study is to find out whether a medicine called verducatib helps people with COPD have fewer flare-ups or sudden worsening of COPD symptoms over up to about 1.5 years, compared with placebo. The study also looks at whether verducatib delays the time until the first flare-up, how well it is tolerated, improves participants' quality of life, and improves their lung function when compared with placebo. In this study, participants are put into 2 groups randomly, which means by chance. One group takes verducatib as tablets and the other group takes placebo tablets. Placebo tablets look like verducatib tablets but do not contain any medicine. Participants take a tablet by mouth once a day for at least 1 year and up to about 1.5 years. All participants continue their regular COPD treatment during the study. Participants are in the study for at least 1 year and up to about 1 year and 8 months. During this time, they have regular visits at the study site and monthly phone calls from the study staff to check on their COPD symptoms and any health problems. Doctors collect information about participants' health, including blood samples. They record how often participants have moderate or severe COPD flare-ups and how long it takes until the first flare-up. They also measure lung function and ask participants to fill in questionnaires about their symptoms and daily life. Participants have to daily report their symptoms and intake of certain medications in an electronic diary at home. The results are compared between the 2 groups to see whether verducatib helps reduce flare-ups and improves symptoms. The doctors also regularly check participants' health and note any unwanted effects.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
VerducatibDrug
Verducatib
Placebo matching verducatibDrug
Placebo matching verducatib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)Time frame: Up to week 76
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Pulmonary Associates - Deer Valley Office
Phoenix, Arizona
IMAX Clinical Trials
La Palma, California
Clinical Research Specialists LLC - Kissimmee
Kissimmee, Florida
Optimus U Corporation-Miami-69452
Miami, Florida
Cordova Research Institute
Miami, Florida
Bolanos Clinical Research
Pembroke Pines, Florida
Appalachian Clinical Research
Adairsville, Georgia
Covenant Pulmonary Critical Care
Atlanta, Georgia
Christie Clinic in Champaign on University
Champaign, Illinois
Brigham and Women's Hospital
Boston, Massachusetts
UMASS Memorial Medical Center
Worcester, Massachusetts
Midwest Clinical Research Center - St. Louis
St Louis, Missouri
Clinical Research Associates of Central PA
DuBois, Pennsylvania
Temple University
Philadelphia, Pennsylvania
Velocity Clinical Research-Union-68888
Union, South Carolina
Clinical Trials Center of Middle Tennessee, LLC
Franklin, Tennessee
Greater Heights & Memorial Pulmonary and Sleep
Houston, Texas
Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico
Milan, Italy
ASST Fatebenefratelli Sacco
Milan, Italy
Azienda Ospedaliera Universitaria "Federico II"
Naples, Italy
Pol. Universitario Tor Vergata
Roma, Italy
Hospital Sultan Idris Shah Serdang
Kajang, Malaysia
Hospital Raja Perempuan Zainab II
Kelantan, Malaysia
Institut Perubatan Respiratori
Kuala Lumpur, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.